Table 1. Sample Characteristics.
| Baseline characteristicsa | Placebo (74) | Arbaclofen (76) | Total (150) |
|---|---|---|---|
| Mean age (SD) | 11.7 (5.0) | 11.4 (4.2) | 11.6 (4.6) |
| Adolescents, age 12–21 years (%) | 36 (48.6%) | 38 (50.0%) | 74 (49.3%) |
| Males (%) | 61 (82.4%) | 63 (82.9%) | 124 (82.72%) |
| IQ >70 (%) | 40 (54.1%) | 36 (47.4%) | 76 (50.7%) |
| Mean ABC-C Lethargy/Social Withdrawal (SD) | 19.3 (8.3) | 20.1 (8.2) | 19.7 (8.2) |
| Concomitant psychoactive medication | 12 (16.2%) | 14 (18.4%) | 26 (17.3%) |
| DSM-IV diagnosis | |||
| Autistic disorder (%) | 61 (82.4%) | 69 (90.8%) | 130 (86.7%) |
| Asperger's disorder (%) | 12 (16.2%) | 5 (6.6%) | 17 (11.3%) |
| PDD-NOS (%) | 1 (1.4%) | 2 (2.6%) | 3 (2.0%) |
| ADOS classification | |||
| Autism (%) | 57 (77.0%) | 63 (82.9%) | 120 (80.0%) |
| Autism spectrum (%) | 16 (21.6%) | 12 (15.8%) | 28 (18.7%) |
| Unable to test (%) | 1 (1.4%) | 1 (1.3%) | 2 (1.3%) |
| Race/ethnicity | |||
| White Non-Hispanic (%) | 45 (60.8%) | 51 (67.1%) | 96 (64.0) |
| White Hispanic (%) | 9 (12.2%) | 10 (13.2%) | 19 (12.7%) |
| African American (%) | 9 (12.2%) | 8 (10.5%) | 17 (11.3%) |
| Asian (%) | 3 (4.1%) | 5 (6.6%) | 8 (5.3%) |
| Other (%) | 8 (10.8%) | 2 (2.6%) | 10 (6.7%) |
Abbreviations: ABC-C, Aberrant Behavior Checklist.
a
No group differences were statistically significant (all p>0.1).